Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy
Circulation · 28.11.2023 · 148 (22) · 1797-1811
DOI: 10.1161/circulationaha.123.065037 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation, erschienen am 28.11.2023. Verfasst von Ethan J Rowin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Lahey Hospital and Medical Center, Burlington, MA (E.J.R., M.S.M., B.J.M.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Cardiomyopathy, Hypertrophic, Catheter Ablation. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 107 Literaturangaben.
Abstract (Originalsprache)
Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of patients. AF in HCM historically has been characterized as a decisive disease complication associated with substantial risk for thromboembolic stroke and increased morbidity and mortality. However, there have been many advances in treatment strategy resulting in improved outcomes for this patient group. For example, stroke risk in HCM has been greatly reduced by using systemic oral anticoagulation initiated after the first clinical (symptomatic) AF episode, usually with preference given to direct anticoagulants over warfarin. In contrast, stroke risk scoring systems (such as CHA 2 DS 2 -VASc score) are not informative in HCM given the substantial potential for stroke events in patients with low scores, and therefore should not be used for anticoagulation decisions in this disease. A novel risk score specifically designed for HCM (HCM-AF score) can reliably identify most patients with HCM at risk for future AF. Although a strategy focused on controlling ventricular rate is effective in asymptomatic (or minimally symptomatic) patients with AF, restoring and maintaining sinus rhythm is required for most patients with marked AF symptom burden and impaired quality of life. Several antiarrhythmic drugs such as sotalol, disopyramide, and amiodarone, can be effective in suppressing AF episodes; albeit safe, long-term efficacy is supported by only limited data. Catheter AF ablation has emerged as an important treatment option for some patients, although freedom from AF after a single ablation is relatively low (35% at 3 years), multiple ablations and the concomitant use of antiarrhythmic drugs can control AF with more than two-thirds of patients maintaining sinus rhythm at 5 years. Surgical AF ablation with biatrial Cox-Maze IV performed as an adjunctive procedure during myectomy can reduce symptomatic AF episodes (70% of patients free from AF at 5 years). For the vast majority of patients who have HCM with AF, the implementation of contemporary therapies has allowed for improved quality of life and low HCM-related mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lahey Hospital and Medical Center, Burlington, MA (E.J.R., M.S.M., B.J.M.).
- University of Texas Southwestern Medical Center, Dallas (M.S.L.).
ORCID-Profile: Ethan J Rowin, Mark S Link, Martin S Maron, Barry J Maron
Zitieren
APA
Rowin, E. J., Link, M. S., Maron, M. S., & Maron, B. J. (2023). Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation, 148(22), 1797-1811. https://doi.org/10.1161/circulationaha.123.065037
Vancouver
Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2023;148(22):1797-1811. doi:10.1161/circulationaha.123.065037
BibTeX
@article{Rowin2023,
author = {Rowin, Ethan J and Link, Mark S and Maron, Martin S and Maron, Barry J},
title = {Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy},
journal = {Circulation},
year = {2023},
volume = {148},
number = {22},
pages = {1797--1811},
doi = {10.1161/circulationaha.123.065037}
}
EUVIMED